Daiichi Sankyo posts 'extraordinary loss' of nearly $1B
Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising demand for its ADCs to third-party manufacturers. The Japanese company ...
May 8, 2026 01:16 PM EDT PharmaManufacturing Daiichi Sankyo posts 'extraordinary loss' of nearly $1B after overestimating need for ADC capacity Anna Brown News Reporter Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an “extraordinary loss” of 149.4 billion Japanese yen ($950 million) after overpromising … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that